✦ LIBER ✦

The Development of Plasma Derivatives for Clinical Use A Symposium Summary

✍ Scribed by Dr. H.F. Deutsch

Book ID: 115107134
Publisher: John Wiley and Sons
Year: 1972
Tongue: English
Weight: 234 KB
Volume: 23
Category: Article
ISSN: 0042-9007
DOI: 10.1111/j.1423-0410.1972.tb03823.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Development of Plasma Derivatives for Cl

Development of Plasma Derivatives for Clinical Use

✍ Dr. J.L. Tullis 📂 Article 📅 1972 🏛 John Wiley and Sons 🌐 English ⚖ 386 KB

A Survey of the Production of Plasma Der

A Survey of the Production of Plasma Derivatives for Clinical Use

✍ Dr. H. G. Schwick 📂 Article 📅 1972 🏛 John Wiley and Sons 🌐 English ⚖ 474 KB

Development and implementation of the ‘c

Development and implementation of the ‘clinical assessment summary’ for providing continuous clinical information

✍ John Reilly; Annette Greenwood; Samuel Margis; Devapriya Rudolph 📂 Article 📅 2003 🏛 Informa plc 🌐 English ⚖ 87 KB

Objective: To describe the development and implementation of a typed ‘continuous’ clinical summary, with a longitudinal formulation and modular episode-based summaries. Methods: Outline of rationale for this form of summary and the implementation process. Results: Despite identified technical

Practical guidelines for the clinical us

Practical guidelines for the clinical use of plasma

✍ Peter Hellstern; Wolfgang Muntean; Wolfgang Schramm; Erhard Seifried; Bjarte G S 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Development of a sclerostin elisa for cl

Development of a sclerostin elisa for clinical use

✍ G. Schett; M. Hennies 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

The OptiMARK clinical development progra

The OptiMARK clinical development program: Summary of safety data

✍ Jeffrey J. Brown; Rita M. Kristy; Gary R. Stevens; Joseph A. Pierro 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

## Abstract ## Purpose To describe and summarize the safety data from the OptiMARK clinical development program. ## Materials and Methods In the 18 clinical studies comprising the clinical program, doses ranging from 0.1 to 0.7 mmol/kg were administered to healthy adult volunteers, patients with